Funding for this research was provided by:
Vetenskapsrådet (2013-07434)
Deutsche Forschungsgemeinschaft (SFB1134-B04)
EC | Horizon 2020 Framework Programme (668863-SyBil-AA)
Article History
Received: 15 March 2019
Revised: 5 July 2019
Accepted: 8 August 2019
First Online: 8 October 2019
Conflict of interest
: M.H. is on the scientific boards of BrainSway Technologies, Aelis Pharma and Adial Pharmaceuticals, and has received consulting or speaker fees from Indivior and Gilead. Remaining authors have no conflicts of interest to disclose.